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Deficiency of complement factor C5 reduces 
early mortality but does not prevent organ 
damage in an animal model of multiple organ 
dysfunction syndrome
Grard A. P. Nieuwenhuiizen, MD; M. P. Desirée Meyer, MD; Thijs Hendriks, PhD; R. Jan A. Goris, MD, PhD
Objective: To evaluate the role of comple­
ment factor C5 in a model of zymosan-induced 
multiple organ dysfunction syndrome.
Design: Experimental animal study.
Setting: Central animal laboratory of a uni­
versity hospital.
Subjects: Twenty-five C5-deficient B2D10/ 
Old and 25 C5-sufficient B2D10/New mice.
Interventions: On day 0, all mice received  
an intraperitoneal injection  w ith zymosan 
suspended in paraffin in a dose of 1 mg/g body 
weight.
Measurements and Main Results: Between  
days 0 and 12, biological parameters (temper­
ature, body weight, and clinical condition) 
were measured daily and mortality was moni­
tored. Clinical condition was assessed as a 
symptom score by blindly grading the degree 
of lethargy, con ju n ctiv itis, diarrhea, and  
ruffled fur of each mouse on a 2-point scale 
(maximum score of 4). On day 12, all surviving 
mice were killed and relative organ weights 
of lungs, liver, spleen, and kidneys were cal­
culated. Relative organ weight was defined as 
(organ weight/body weight) x 100%.
Zymosan administration induced a typical 
triphasic illness. Deterioration of the clinical 
condition, as indicated by the symptom score, 
and the decrease in temperature and body 
weight in the acute phase were all signifi­
cantly less severe in C5-deficient mice (p < 
.005). In the late phase, no differences could 
be noticed in the courses of these biological
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parameters. Overall m ortality was 2 (8%) of 25 
in  C5-deficient mice and 8 (32%) of 25 in 05- 
sufficient mice (p = .049), a difference that was 
mainly due to a difference in  the acute phase. 
Organ damage, assessed as the relative organ 
weights, did not show any statistical differ­
ences for any organ betw een both strains.
Conclusions: Complement factor C5 appears 
to play an important role in  the acute hyper­
dynamic septic response in  this model. How­
ever, deficiency of C5 could not prevent organ 
damage in the late m ultiple organ dysfunc­
tion syndrome phase. This finding suggests 
that other factors must be more important in 
the development of the inflammatory response 
leading to m ultiple organ dysfunction syn­
drome. (Crit Care Med 1995; 23:1686-1693)
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Despite advances in intensive care treatment, 
multiple organ dysfunction syndrome and the adult 
respiratory distress syndrome (ARDS) still remain 
the most common causes of death in patients admit­
ted to a surgical intensive care unit after major 
abdominal surgery, acute pancreatitis or severe 
trauma (1). It has been hypothesized that multiple 
organ dysfunction syndrome and ARDS could be 
the result of a generalized excessive autodestructive 
inflammatory response (2). Since the complement 
system is an important initiator and mediator of the 
inflammatory response (3), an excessive activation 
of the complement system has been implicated in 
the pathogenesis of multiple organ dysfunction
syndrome and ARDS (4-7).
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The complement system consists of at least 25 
plasma proteins, formed by the liver and macro­
phages (4, 8-10). Two pathways of complement acti­
vation currently are recognized: the classical path­
way, which is activated by antigen-antibody 
complexes (11), and the alternative pathway, which 
is activated by foreign material and tissue injury
(12). Both pathways converge at the breakdown of 
C3, the subsequent cleavage of C5, and the activa­
tion of the final common pathway (3, 4). C5 is 
divided enzymatically into C5a and C5b. C5a is both 
an anaphylatoxin and a chemotactic agent. The 
latter function is probably the most important since 
C5a is rapidly converted into C5a desarginine (des 
Arg), with concomitant loss of its anaphylatoxic 
activity. Its chemotactic activity stimulates activa­
tion, aggregation and adherence of polymorpho­
nuclear granulocytes to the endothelium with sub­
sequent degranulation and release of oxygen radicals
(13), vasoactive substances, and a variety of pro- 
teinases which can cause endothelial damage (3,14, 
15), resulting in generalized edema. The chemotac­
tic activity of C5a and C5a des Arg is specifically 
enhanced by Gc-globulin and is inactivated by 
chemotactic factor inactivator (16, 17). Pro- 
inflammatory cells possess a receptor for C5a (18). 
In addition to many inflammatory functions, C5a 
also has immunoregulatory activities. For example, 
C5a induces the release of interleukin (IL)-6 by
some
(mainly B-glucan and a-mannan)
teins, 7% lipids, an 
Classically, zymosan
components (31).
complement
(32). Unopsonized zymosan also stimulates macro­
phages to the release of various inflammatory me­
diators (33). The interaction between zymosan and 
macrophages appears to be mediated by three classes 
of cell surface receptors, namely, the mannose/ 
fucose receptor (34), the |3~glucan receptor (35), and 
the CR3 (CDllb/CD18) receptor (36).
In this model, interruption of complement activation 
could theoretically lead to an attenuation of the in­
flammatory response which leads to the development 
of multiple organ dysfunction syndrome.
In used C5-
mice
development of multiple organ dysfunction 
syndrome.
MATERIALS AND METHODS
Zymosan. Zymosan A (Sigma Chemicals, St. Louis, 
MO) was irradiated with 5 kGy and suspended (2.5 
g/100 mL) by high frequency vibration in liquid 
paraffin, for 60 mins at 40°C. This suspension was 
sterilized by incubation in a waterbath at 100°C for
stimulated monocytes (19-21) and stimulates the 80 mins. Sterility was confirmed by aerobic incuba-
production of IL-1 after binding to macrophages 
(19, 22).
tion on blood-agar plates for two days at 37°C. 
Before utilization, the zymosan was warmed to 40°C
C5b participates together with C6, C7, C8, and 
C9 in the formation of the terminal complement 
complex. The terminal complement complex exists 
in two analogous forms. One form exists in a fluid 
phase in combination with the S-protein: this com­
plex is nonlytic, and can be detected in plasma and 
inflammatory fluids (19, 22-24). The other form is 
the membrane attack complex, which can cause 
cell-lysis by penetrating lipid membranes such as 
the endothelium (25). Excessive complement acti­
vation can thus result in a generalized endothelial 
damage with a subsequent generalized permeability 
edema and organ injury (13).
We have developed a model of multiple organ 
dysfunction syndrome in which an intraperitoneal 
injection of zymosan suspended in paraffin leads to 
a generalized inflammatory response and histo­
pathologic changes closely resembling the clinical 
entity of multiple organ dysfunction syndrome (26). 
This model has been validated in our laboratory 
and by others (27-30). Zymosan is a particulate cell 
wall product of the yeast, Saccharomyces cerevisiae,
and vibrated in a high-frequency waterbath for 15 
mins.
Animals. B10D2/01d.Sn and B10D2/New.Sn mice 
were obtained from Jackson Laboratories (Bar Har­
bor, ME) and from Harlan Olac Limited (Bicester, 
UK), respectively. B10D2/01d.Sn mice are congeni­
tally CS-deficient by a deletion mutation on chro­
mosome 2 (37), The B10D2/New.Sn mouse is the 
coisogenetic twin of the B10D2/01d.Sn mouse, but 
without the mutation on chromosome 2 (37),
C5 deficiency in B10D2/01d.Sn mice was shown 
to be accompanied by an almost complete absence of 
hemolytic complement activity (38). Only male mice 
were used, because female mice were reported not 
to be consistent in their C5 concentrations (39).
Throughout the experiment, all mice were al­
lowed free access to water acidified with hydrochlo­
ric acid to a pH of 3 and were fed standard labora­
tory chow (RMH-GS pellets, Hope Farms, Woerden, 
The Netherlands) irradiated at 10 kGy. Room tem­
perature was kept constant at 21°C and a 12-hr 
lighting cycle was maintained. The experiments
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were approved by the Animal Care Comittee of the 
Medical Faculty of Nijmegen.
Experimental Design. Twenty-five C5-deficient 
mice (B10D2/01d.Sn.), 14 wks old and weighing 19 
to 32 g, and 25 control mice (B10D2/New.Sn.), 12 
wks old and weighing 22 to 29 g, were adapted to 
handling 2 wks before the start of the experiment. 
On day 0 of the experiment, all mice received an 
aseptic intraperitoneal injection of zymosan in a 
dose of 1 mg/g body weight. Between days 0 and 12, 
body temperature, body weight, and clinical condi­
tion were measured and monitored daily. Clinical 
condition was assessed as a symptom score by grad­
ing the severity of conjunctivitis, diarrhea, ruffled 
fur, and lethargy in a blinded fashion on a 2-point 
scale (0 = none, 1 = present; minimum = 0, maxi­
mum = 4). Mortality rate was monitored daily. On 
day 12 , all surviving mice were anesthetized with 
ether and bled by retro-ocular puncture. The abdo­
men was opened, using a sterile technique, and 
samples of the peritoneal fluid were collected for 
aerobic and anaerobic culture on blood-agar plates 
for 2 days at 37°C. Subsequently, lungs with tra­
chea, spleen, liver, and kidneys were inspected, 
dissected free, and weighed.
Relative organ weights were calculated using the 
formula: (organ weight/body weight) x 100%. In 
mice that died prematurely before day 12, no anaero­
bic cultures were performed from the peritoneal 
fluid because post mortem anaerobic overgrowth 
could be expected.
Statistical Analysis. Statistical analysis of bio­
logical parameters (body temperature, body weight, 
and symptom score) was performed using the distri- 
bution-free curve analysis according to Koziol et al 
(40). Since the zymosan-induced illness is charac­
terized by distinct phases, comparisons were made 
both for the acute phase (days 0 to 4), and the late 
phase (days 8 to 12). Relative organ weights were 
compared, using the distribution-free Wilcoxon’s two 
sample test. Noncontinuous data (mortality rate) 
were analyzed, using Fisher’s exact test. Differ­
ences between groups were considered to be statis­
tically significant at p < .05.
RESULTS
Biological Measurements. Intraperitoneal admin­
istration of zymosan induced a typical triphasic 
clinical illness, depicted in Figure 1 as the course of 
the symptom scores. In the acute phase (days 0 to 
4), the mice became lethargic and anorectic, 
hyperventilated, lost hemorrhagic fluid from the 
nose and conjunctivae, and had diarrhea. According
to the symptom score, C5-deficient animals dis­
played significantly less severe (p < .0001) symp­
toms than C5-sufficient mice. After 3 days, the con­
dition of the surviving mice improved: they became 
more active, showed no signs of conjunctivitis or 
diarrhea, and their fur was only slightly ruffled. 
Recovery of C5-deficient mice appeared to be quicker. 
However, after 8 days, the clinical condition of the 
mice deteriorated progressively. They became more 
lethargic and started to lose hemorrhagic fluids 
from the nostrils and conjunctivae. C5-deficient mice 
deteriorated significantly slower (p < .0001) than 
their C5 sufficient controls.
Figure 1 shows that body temperature declined 
dramatically in C5-sufficient mice the first day af­
ter zymosan injection. C5-deficient mice, however, 
showed little decrease (p < .001) in temperature. 
After a recovery phase, temperature decreased again 
in the late phase. At this time no significant differ­
ences were noticed between the two groups.
The course of body weight was also triphasic, as 
shown in Figure 1. Body weight decreased in the 
acute phase. Recovery in C5-deficient mice was sig­
nificantly better (p < .0001) than in the OS-suffi­
cient controls. After this recovery phase, body weight 
decreased again in both groups, with a less serious 
decrease in C5-deficient mice. However, this differ­
ence did not reach statistical significance (p = .0552).
Survival Rates, Survival rates for both groups 
are depicted in Figure 1. In the acute phase, seven 
C5-sufficient mice died vs. one C5-deficient mouse. 
No mice died in the recovery phase. In the late 
phase, one mouse died in each group. Overall mor­
tality was 8% (two of 25) in C5-deficient mice and 
32% (8 of 25) in C5-sufficient controls (p = .049), due 
mainly to the difference observed in the acute phase.
Macroscopic Appearance of the Organs and Rela­
tive Organ Weights. After samples of the peritoneal 
fluid had been taken for anaerobic and aerobic bac­
terial cultures, the organs were dissected free and 
inspected. The organs of the mice that died in the 
acute phase showed little abnormalities. The lungs 
were hyperemic and the abdomen showed few or no 
adhesions. No differences were noticed between groups.
The lungs of mice that died in the late phase or 
that were killed on day 12 were extremely 
hyperemic, with hemorrhagic spots, and occasion­
ally, extensive hemorrhagic infarction. The abdo­
men showed signs of an extensive fibroplastic peri­
tonitis with massive adhesions.
Although the C5-sufficient control mice showed 
the most extensive macroscopic abnormalities, no 
significant differences were found with the C5~ 
deficient mice (data not shown).
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Figure 1. A) Clinical condition of the surviving mice assessed as the symptom score by grading the severity of conjunctivitis, diarrhea,
ruffled fur, and lethargy in a blinded fashion on a 2-point scale (0 = none, 1 = present; minimum = 0, maximum = 4). Complement factor 
05-deficient mice showed significantly less symptoms in the acute and late phase (curve analysis according to Koziol). B) Body 
temperature of the surviving mice calculated as the percentage change when compared with day 0. In contrast to complement factor 06- 
sufficient controls, complement factor CS-deficient mice showed a significantly smaller decrease in temperature in the early phase. No 
significant differences were noticed in the late phase (curve analysis according to Koziol). C) Body weight of the surviving mice calculated 
as the percentage change when compared with day 0. Recovery in the early phase was significantly better in the complement factor 05- 
deficient mice. No significant differences were noticed in the late phase (curve analysis according to Koziol). D) Survival rate after 
injection of zymosan on day 0. Overall mortality rate was significantly lower (p = .049 by Fisher’s exact test) in complement factor 05- 
deficient mice mainly due to a difference in the acute phase. In all graphs, the solid, circles indicate complement factor OS-sufficient 
controls and the open circles indicate complement factor 05-deficient mice. Values in graphs A through C are expressed as mean ± h k m .
Organ damage of the surviving mice, assessed as 
the increase in relative organ weights of lungs, 
liver, spleen and kidneys is depicted in Figure 2. No 
significant differences were found between the two 
strains.
Bacteriology. All cultures of the peritoneal fluid 
of the surviving mice were sterile, thereby indicating
the absence of bacterial peritonitis.
DISCUSSION
Both clinical and experimental data have sug­
gested a relationship between activation of the 
complement system and the pathogenesis of septic 
shock, ARDS, and multiple organ dysfunction syn­
drome. During septic shock, most clinical studies 
have shown an activation of C5a. However, data are
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complement complex formation could be a good pre­
dictor of ARDS (47). Other studies (43, 48, 49) could
not confirm a relationship between C5a or terminal
complement complex formation 
ment of ARDS or mortality from
develop-
possible
development of 
drome. Heideman and Hugli
l complement activation and the 
multiple organ dysfunction syn-
of C3a
C4a, but not of C5a, with the development of mul­
tiple organ dysfunction syndrome. Nuytinck et al. 
(6) showed a good correlation between the multiple 
organ failure score and early Clq, C3, C3 pro acti­
vator and C4 concentrations, but not with C5a con-
Roumen demonstrated 
at trauma tha
Figure 2. Relative organ weights 12 days after zymosan injec­
tion. Relative organ weights were calculated using the formula: 
(organ weight/body weight) x 100%. Solid bars, complement fac­
tor C5-sufficient controls; stippled bars, complement factor C5- 
deficient mice. No significant differences were noticed in terms of 
the organ damage of the surviving mice (Wilcoxon’s two-sample 
test). Organ weights are expressed as percentage of body weight. 
Data are expressed as mean ± sem.
early increase in C3a and terminal complement 
complex concentrations early after severe blunt 
trauma were associated with the development of 
multiple organ dysfunction syndrome. However, only 
C3a/C3 ratios early after trauma, and not terminal 
complement complex concentrations, were associ­
ated with mortality.
In most clinical studies, it is difficult to interpret 
measured concentrations of C5a since C5a, and to a
conflicting when C5a is correlated to prognosis. 
Successful treatment of septic shock was associated 
with a normalization of the C5a/C5a des Arg ratio 
and terminal complement complex concentrations, 
but not of C5a concentrations (25, 41). Other stud­
ies (42, 43) could not confirm that the severity or 
mortality of sepsis is correlated with a persistent 
increase in C5a concentrations. On the other hand, 
a strong correlation was found between increased 
plasma concentrations of C5a and the development 
of ARDS (44), while C5a concentrations correlated 
with the severity of pulmonary failure (4-5). It also 
has been demonstrated that C5a is increased in 
bronchoalveolar lavage fluid in patients developing 
ARDS, with a normalization after ARDS had re­
solved (16). Chemotactic factor inactivator, which 
decreases C5a-directed neutrophil chemotaxis, has 
been shown to be markedly increased in ARDS 
bronchoalveolar lavage fluid. However, chemotactic 
factor inactivator-functional activity was markedly 
decreased, suggesting that patients with ARDS are 
functionally deficient in chemotactic factor 
inactivator, with a subsequent increased ability of 
C5a to attract neutrophils (46). Plasma terminal 
complement complex concentrations have been 
shown to be increased 2 days before the onset of 
ARDS in septic patients and to be decreased imme-
lesser extent, C5a des Arg, are relatively unstable
molecules
C5a
from
serum
Furthermore, C5a des Arg is rapidly bound and 
removed from plasma by neutrophils (51). The con­
flicting results concerning the correlation between 
septic shock, ARDS, and multiple organ dysfunc­
tion syndrome, and the activation of C5a might be
explained by this observation.
In order to find a possibl* 
between complement activati 
ment of septic shock. ARDS,
causal relationship
multiple
syndrome, experiments
formed with complement depletion and, more spe­
cifically, C5 depletion by using C5-deficient animals 
or using antibodies against C5a. In a porcine endot- 
oxic shock model (52), complement depletion with 
Naja haje cobra venom factor significantly improved 
cardiac index and visceral perfusion. In another 
porcine model (53) using a continuous infusion with 
Pseudomonas aerusinosa. complement
resulted in less pulmonary
model of sepsis 
(54), treatment
failure. In a primate 
fusion of Escherichia coli 
and during infusion with
C5a-antibodies resulted in a reduction of mor
diately after resolution, suggesting that terminal tality, an attenuation of ARDS and decreases in the
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systemic manifestations of sepsis. Peak C5a concen­
trations were decreased and no significant differ­
ences were seen in C3a or C4a concentrations (55). 
These experiments were confirmed by others in an 
endotoxic rat model (56) in which anti-C5a-antibod- 
ies attenuated the hypotensive and vascular perme­
ability changes after endotoxin-induced shock. C5- 
deficient B10D2/new mice showed less septic lung 
injury and less early mortality in the cecal ligation 
and puncture model, although total mortality was 
equal to that in C5-sufficient B10D2/old mice (37). 
In another study (57), it was demonstrated that C5- 
deficient mice were protected from combined tumor 
necrosis factor-endotoxin-induced mortality, shock, 
hypothermia, hemoconcentration and bowel injury. 
The latter study (57) also showed the importance of 
C5 since C3-deficient mice were not protected.
The present study shows that C5-deficient mice 
displayed an attenuated response in the acute hy­
perdynamic septic phase, as measured by the re-
C5a is not the decisive factor associated with the 
development of multiple organ dysfunction syndrome 
in this model, and that other factors such as macro­
phage activation may be more important in this 
respect. Clinical indications, suggesting the impor­
tance of macrophage activation, are the association 
between neopterin concentrations and a poor out­
come in sepsis and multiple trauma patients (60, 
61). Neopterin is a stable inactive end product of 
macrophage metabolism and a marker of macro­
phage activity, A recent study (50) has shown that 
early after severe blunt trauma, neopterin/creati­
nine ratios were not significantly higher in patients 
developing multiple organ dysfunction syndrome. 
However, from 8 days after trauma, these ratios 
were significantly higher in those patients. This 
finding suggests that a late activation of macro­
phages is associated with the development of mul­
tiple organ dysfunction syndrome. In the TNF- 
endotoxin-model, C5-deficient mice were protected
duction in the symptom score, hypothermia, and from TNF-endotoxin effects. However, when the
decrease in body weight. Overall mortality was re­
duced, but this reduction was mainly due to a de­
crease in the acute phase. This finding suggests
TNF dose was increased, no protection occurred, 
suggesting that high doses of TNF act independent 
of the complement system (57). This finding shows
that C5a might be an important mediator in the 
acute hyperdynamic septic response in this model. 
This conclusion is in agreement with the above 
mentioned clinical studies in which a possible rela­
tionship is suggested between C5a activation and
that experimentally, other, more potent factors could 
be implicated in the pathogenesis of multiple organ 
dysfunction syndrome. Further support for this hy­
pothesis comes from the fact that in our model, 
mortality could be reduced by elimination of liver
septic shock. It is also in line with the reported 
attenuation of the acute response in experimental 
studies with cecal ligation and puncture and TNF-
and splenic macrophages with liposome encapsu­
lated dichloro-methylene-diphosphonate before zy­
mosan administration, suggesting that macrophage
or endotoxin-induced sepsis. It has been suggested activation is also an important mediator (62).
that C5a modulates the endotoxin-triggered TNF 
response. Endotoxin administration in CS-deficient 
mice resulted in markedly lower serum TNF-activ­
ity when compared with Cö-sufficient mice (58). 
Since TNF production has been documented in the 
acute phase of our model, and pretreatment with 
anti-TNF antibodies could attenuate the acute re-
We thus conclude that C5 deficiency attenuates 
the acute hyperdynamic response, but does not pre­
vent organ damage in a model of zymosan-induced 
generalized inflammation. Thus, C5 is not the only 
factor involved in the late inflammatory response 
leading to multiple organ dysfunction syndrome.
sponse (59), the attenuation seen in C5-deficient 
mice could be TNF-mediated. However, late organ 
damage, as measured by the relative organ weights, 
was not reduced, suggesting that C5a might not be 
an important mediator in the late hypodynamic 
phase of this model. This finding is in agreement 
with the few clinical studies in which no relationship 
could be found between C5a activation and multiple 
organ dysfunction syndrome (5, 6). It is also in line 
with the studies done in the cecal ligation and punc­
ture model where overall mortality did not decrease 
despite a decrease in acute mortality (37).
Since zymosan is also an important stimulator of 
macrophages (33), we hypothesize that activation of
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